Shares of Neurogene Inc. (NASDAQ:NGNE – Get Free Report) have been assigned a consensus recommendation of “Buy” from the nine ratings firms that are covering the firm, MarketBeat.com reports. Eight research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 12 month price objective among brokers that have covered the stock in the last year is $51.00.
Separately, HC Wainwright cut their price objective on shares of Neurogene from $51.00 to $49.00 and set a “buy” rating for the company in a research report on Monday, August 12th.
View Our Latest Stock Report on NGNE
Institutional Investors Weigh In On Neurogene
Neurogene Stock Performance
Neurogene stock opened at $48.37 on Wednesday. Neurogene has a 12-month low of $12.49 and a 12-month high of $55.21. The company has a 50-day moving average price of $41.85 and a 200 day moving average price of $38.19.
Neurogene (NASDAQ:NGNE – Get Free Report) last released its quarterly earnings data on Friday, August 9th. The company reported ($1.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.02) by ($0.07). The company had revenue of $0.93 million for the quarter. On average, equities research analysts expect that Neurogene will post -4.47 earnings per share for the current fiscal year.
About Neurogene
Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.
Featured Stories
- Five stocks we like better than Neurogene
- What is a Bond Market Holiday? How to Invest and Trade
- Texas Roadhouse Stock Steering for New Highs This Year
- Why Invest in 5G? How to Invest in 5G Stocks
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- Quiet Period Expirations Explained
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
Receive News & Ratings for Neurogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurogene and related companies with MarketBeat.com's FREE daily email newsletter.